XyloCor Therapeutics, Inc.
XyloCor Therapeutics is a biopharmaceutical company focused on advancing gene therapy for cardiovascular diseases, particularly for patients with refractory angina and other unmet medical needs. Their mission is to improve lives through scientific innovation in gene therapy, with a vision to transform outcomes for patients suffering from coronary artery disease.
Industries
Nr. of Employees
small (1-50)
XyloCor Therapeutics, Inc.
411 Swedeland Road, Suite 23-1080, King of Prussia, PA 19406
Products
XC001
An investigational gene therapy designed to stimulate the formation of new blood vessels in the heart to bypass diseased vessels and improve blood flow, potentially reducing chest pain and improving quality of life in patients with refractory angina.
XC002
A secondary preclinical investigational product being developed for the treatment of patients with cardiac tissue damage from heart attacks.
XC001
An investigational gene therapy designed to stimulate the formation of new blood vessels in the heart to bypass diseased vessels and improve blood flow, potentially reducing chest pain and improving quality of life in patients with refractory angina.
XC002
A secondary preclinical investigational product being developed for the treatment of patients with cardiac tissue damage from heart attacks.
News & Updates
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
XyloCor and SmartCella have entered into a licensing agreement for the Extroducer® Infusion Catheter System, a device designed to deliver gene therapy directly into the heart, supporting catheter-based delivery of XC001 in future clinical studies and commercial use.
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Gene Therapy XC001
The financing will support two Phase 2 clinical trials of XC001 for refractory angina, using a non-surgical method of endocardial administration via a novel injection catheter.
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
XyloCor plans to deploy the Extroducer catheter to support catheter-based endocardial delivery of XC001, aiming to improve safety and efficacy.
XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001
The trial demonstrated that XC001 can be safely administered and showed improvements in exercise duration, ischemic burden, and angina frequency in patients with refractory angina.
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at ESC Congress 2023
Results showed XC001 was well tolerated, with no serious adverse events, and demonstrated improvements in exercise time, ischemia, and symptoms.
XyloCor Therapeutics Reports Sustained 12-Month Data from Phase 2 EXACT Trial of XC001
Durable improvements in exercise capacity and reductions in ischemic burden and symptoms were observed at 12 months.
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
XyloCor and SmartCella have entered into a licensing agreement for the Extroducer® Infusion Catheter System, a device designed to deliver gene therapy directly into the heart, supporting catheter-based delivery of XC001 in future clinical studies and commercial use.
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Gene Therapy XC001
The financing will support two Phase 2 clinical trials of XC001 for refractory angina, using a non-surgical method of endocardial administration via a novel injection catheter.
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
XyloCor plans to deploy the Extroducer catheter to support catheter-based endocardial delivery of XC001, aiming to improve safety and efficacy.
XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001
The trial demonstrated that XC001 can be safely administered and showed improvements in exercise duration, ischemic burden, and angina frequency in patients with refractory angina.
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at ESC Congress 2023
Results showed XC001 was well tolerated, with no serious adverse events, and demonstrated improvements in exercise time, ischemia, and symptoms.
XyloCor Therapeutics Reports Sustained 12-Month Data from Phase 2 EXACT Trial of XC001
Durable improvements in exercise capacity and reductions in ischemic burden and symptoms were observed at 12 months.